Logo image of CLRB

CELLECTAR BIOSCIENCES INC (CLRB) Stock Fundamental Analysis

NASDAQ:CLRB - Nasdaq - US15117F8077 - Common Stock - Currency: USD

4.61  +0.17 (+3.83%)

After market: 4.72 +0.11 (+2.39%)

Fundamental Rating

1

Overall CLRB gets a fundamental rating of 1 out of 10. We evaluated CLRB against 550 industry peers in the Biotechnology industry. CLRB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CLRB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CLRB had negative earnings in the past year.
CLRB had a negative operating cash flow in the past year.
In the past 5 years CLRB always reported negative net income.
CLRB had a negative operating cash flow in each of the past 5 years.
CLRB Yearly Net Income VS EBIT VS OCF VS FCFCLRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

CLRB's Return On Assets of -152.99% is on the low side compared to the rest of the industry. CLRB is outperformed by 84.91% of its industry peers.
The Return On Equity of CLRB (-254.72%) is worse than 70.73% of its industry peers.
Industry RankSector Rank
ROA -152.99%
ROE -254.72%
ROIC N/A
ROA(3y)-220.55%
ROA(5y)-150.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLRB Yearly ROA, ROE, ROICCLRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

CLRB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLRB Yearly Profit, Operating, Gross MarginsCLRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, CLRB has more shares outstanding
Compared to 5 years ago, CLRB has more shares outstanding
There is no outstanding debt for CLRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLRB Yearly Shares OutstandingCLRB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
CLRB Yearly Total Debt VS Total AssetsCLRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

CLRB has an Altman-Z score of -29.88. This is a bad value and indicates that CLRB is not financially healthy and even has some risk of bankruptcy.
CLRB's Altman-Z score of -29.88 is on the low side compared to the rest of the industry. CLRB is outperformed by 88.36% of its industry peers.
There is no outstanding debt for CLRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.88
ROIC/WACCN/A
WACCN/A
CLRB Yearly LT Debt VS Equity VS FCFCLRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

CLRB has a Current Ratio of 2.47. This indicates that CLRB is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.47, CLRB is not doing good in the industry: 70.91% of the companies in the same industry are doing better.
CLRB has a Quick Ratio of 2.47. This indicates that CLRB is financially healthy and has no problem in meeting its short term obligations.
CLRB's Quick ratio of 2.47 is on the low side compared to the rest of the industry. CLRB is outperformed by 68.73% of its industry peers.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 2.47
CLRB Yearly Current Assets VS Current LiabilitesCLRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

CLRB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -120.96%.
EPS 1Y (TTM)-120.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-467.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -14.38% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-464.09%
EPS Next 2Y-136.42%
EPS Next 3Y-69.12%
EPS Next 5Y-14.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLRB Yearly Revenue VS EstimatesCLRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M
CLRB Yearly EPS VS EstimatesCLRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLRB Price Earnings VS Forward Price EarningsCLRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLRB Per share dataCLRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A cheap valuation may be justified as CLRB's earnings are expected to decrease with -69.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-136.42%
EPS Next 3Y-69.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLRB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTAR BIOSCIENCES INC

NASDAQ:CLRB (8/12/2025, 8:00:00 PM)

After market: 4.72 +0.11 (+2.39%)

4.61

+0.17 (+3.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)10-27 2025-10-27/bmo
Inst Owners6.58%
Inst Owner Change-19.94%
Ins Owners1.6%
Ins Owner Change1.89%
Market Cap12.35M
Analysts80
Price Target122.4 (2555.1%)
Short Float %N/A
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.64%
Min EPS beat(2)15.96%
Max EPS beat(2)83.31%
EPS beat(4)3
Avg EPS beat(4)46.37%
Min EPS beat(4)-5.28%
Max EPS beat(4)91.47%
EPS beat(8)3
Avg EPS beat(8)10.55%
EPS beat(12)5
Avg EPS beat(12)10.78%
EPS beat(16)9
Avg EPS beat(16)10.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3900%
PT rev (3m)2017.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2500%
EPS NY rev (1m)0%
EPS NY rev (3m)-2466.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.28
P/tB 1.28
EV/EBITDA N/A
EPS(TTM)-6.43
EYN/A
EPS(NY)-16.6
Fwd EYN/A
FCF(TTM)-16.3
FCFYN/A
OCF(TTM)-16.27
OCFYN/A
SpS0
BVpS3.6
TBVpS3.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -152.99%
ROE -254.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-220.55%
ROA(5y)-150.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 2.47
Altman-Z -29.88
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)212.71%
Cap/Depr(5y)154.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-120.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-467.57%
EPS Next Y-464.09%
EPS Next 2Y-136.42%
EPS Next 3Y-69.12%
EPS Next 5Y-14.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.37%
OCF growth 3YN/A
OCF growth 5YN/A